Drug Profile
Research programme: pleuromutilins - Nabriva Therapeutics
Alternative Names: BC-7634; BC-9074; BC-9529; BC-9563; ESP - Nabriva; Extended spectrum pleuromutilins - NabrivaLatest Information Update: 08 Jun 2021
Price :
$50
*
At a glance
- Originator Nabriva Therapeutics
- Class Antibacterials
- Mechanism of Action Bacterial protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Austria (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Austria (PO)
- 24 Apr 2015 Antimicrobial data from a preclinical trial in Bacterial infections released by Nabriva